Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CNSP
CNS Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:30 PM EDT
1.12USD-0.444%(-0.01)39,539
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 8, 2025 9:04:30 AM EDT
1.13USD+0.462%(+0.01)1,599
After-hours
May 7, 2025 4:08:30 PM EDT
1.11USD-1.333%(-0.02)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
05:20AM EST  CNS Pharma S-3 Shows Registration For ~24.8M Share Common Stock Offering Via Selling Shareholders   Benzinga
Jan 20, 2022
08:45AM EST  CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference   PR Newswire
Jan 10, 2022
05:00PM EST  CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced   PR Newswire
Jan 7, 2022
08:05AM EST  CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference   PR Newswire
Jan 6, 2022
02:33PM EST  Mid-Afternoon Market Update: Gold Drops 2%; Berkeley Lights Shares Plummet   Benzinga
12:11PM EST  Mid-Day Market Update: Nasdaq Turns Higher; Vocera Communications Shares Surge   Benzinga
08:24AM EST  The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales   Benzinga
07:18AM EST  CNS Pharma Announces $11.5 Mln Private Placement Priced At-the-Market Under Nasdaq Rules   RTTNews
07:03AM EST  CNS Pharmaceuticals Announces $11.5M Private Placement Priced At-the-Market Under Nasdaq Rules   Benzinga
07:01AM EST  CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced   PR Newswire
Dec 2, 2021
08:37AM EST  CNS Gets Approval From Switzerland Ethics Committee For Potentially Pivotal Study Of Berubicin For Treatment Of GBM   RTTNews
08:36AM EST  CNS Pharma Reports Received Approval From Switzerland Ethics Committee For Pivotal Study Of Berubicin For Treatment Of Glioblastoma Multiforme   Benzinga
08:35AM EST  Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)   PR Newswire
Nov 16, 2021
08:02AM EST  CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event   PR Newswire
Oct 11, 2021
08:12AM EDT  CNS Pharmaceuticals Inc. Featured In Syndicated Broadcast Covering Dosing Of First Patients In Its Berubicin Clinical Development Program For Glioblastoma Multiforme   Benzinga
08:00AM EDT  CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering   GlobeNewswire Inc
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
08:32AM EDT  CNS Pharmaceuticals Inc. (CNSP) announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme or GBM, one of the most aggressive types of brain cancer.   RTTNews
08:09AM EDT  CNS Pharmaceuticals Doses First Group Of Patients With Berubicin, An FDA-Designated Fast Track Drug Candidate, In The Potentially Pivotal Study For The Treatment Of Glioblastoma Multiforme   Benzinga
08:08AM EDT  CNS Doses First Group Of Patients With Berubicin In Potentially Pivotal Study For Treatment Of Glioblastoma Multiforme   RTTNews
08:05AM EDT  FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)   PR Newswire
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
08:11AM EDT  CNS Pharmaceuticals 1H Net Loss $3.8M   Benzinga
08:05AM EDT  CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides   PR Newswire
Jul 12, 2021
07:33AM EDT  WPD Pharmaceuticals' Licensor CNS Pharmaceuticals Receives FDA Fast Track Designation For Berubicin For The Treatment Of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans   Benzinga
Jul 1, 2021
09:07AM EDT  CNS Pharma Reports Corporate Update   Benzinga
09:07AM EDT  CNS To Execute On Corporate, Regulatory Strategies To Drive Berubicin Towards Commercialization For Treatment Of GBM   RTTNews
09:05AM EDT  Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM   PR Newswire
Jun 29, 2021
09:25AM EDT  The U.S. Food and Drug Administration granted Fast Track Designation for CNS Pharmaceuticals Inc.'s (CNSP) lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme or GBM.   RTTNews
08:37AM EDT  CNS Pharma: FDA Grants Fast Track Designation For Berubicin For Treatment Of Recurrent Glioblastoma Multiforme   RTTNews
08:36AM EDT  CNS Pharma Reports Received Fast Track Designation From FDA For Its Berubicin For Treatment Of Recurrent Glioblastoma Multiforme   Benzinga
08:35AM EDT  FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the   PR Newswire
Jun 17, 2021
09:07AM EDT  CNS Pharmaceuticals Announces Inclusion In The Russell 2000 Index   Benzinga
May 19, 2021
08:18AM EDT  CNS Pharmaceuticals Opens Enrollment For Potentially Pivotal Study Evaluating Berubicin In Treatment Of Recurrent GBM   RTTNews
08:10AM EDT  CNS Pharmaceuticals Commences Patient Enrollment In Potentially Pivotal Study Of Berubicin   Benzinga
08:05AM EDT  CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study   PR Newswire
May 14, 2021
09:07AM EDT  CNS Pharmaceuticals Q1 Net Loss $3.6M   Benzinga
09:05AM EDT  CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides   PR Newswire
May 11, 2021
08:35AM EDT  CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit   PR Newswire
Mar 15, 2021
09:01AM EDT  CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual   PR Newswire
Mar 4, 2021
09:01AM EST  CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences   PR Newswire
Feb 25, 2021
09:05AM EST  CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021   PR Newswire
Feb 24, 2021
07:36AM EST  WPD Pharmaceuticals Announces Berubicin Supply Agreement With CNS Pharmaceuticals   Benzinga
Feb 18, 2021
01:47PM EST  Polish Regulatory Authority Issues Positive Opinion For CNS Pharma's Brain Cancer Candidate   Benzinga
09:22AM EST  CNS Pharma, WPD Pharma Report WPD Received Positive Opinion Of Lower Silesian Medical Chamber Ethics Committee In Poland For Its Planned Upcoming Berubicin Trial For Adults With Glioblastoma   Benzinga
09:05AM EST  Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study   PR Newswire
Feb 2, 2021
10:32AM EST  Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10   Benzinga
Jan 27, 2021
04:04PM EST  CNS Pharmaceuticals Inc Files For Mixed Shelf Of Up To $75M   Benzinga
Jan 13, 2021
08:30AM EST  InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS   GlobeNewswire Inc
Jan 7, 2021
08:30AM EST  CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference   PR Newswire
Dec 28, 2020
08:03AM EST  CNS Pharmaceuticals Says its FDA Approval of an Investigational New Drug Application Was Covered by Media Outlet NetworkNewsAudio   Benzinga
08:00AM EST  CNS Pharmaceuticals Featured in Syndicated Broadcast Covering   GlobeNewswire Inc
Dec 23, 2020
09:02AM EST  CNS Pharmaceuticals Inc. (CNSP) said Wednesday that it has priced its underwritten public offering of 5 million shares of common stock and warrants to purchase up to 2.50 million shares of common stock.   RTTNews
08:33AM EST  CNS Pharmaceuticals Prices $10.0 Mln Public Offering   RTTNews
08:32AM EST  CNS Pharma Prices 5M Shares, Warrants For 2.5M Shares At $2/Share   Benzinga
08:30AM EST  CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering   PR Newswire
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
04:08PM EST  CNS Pharma Reports Will Host Live Call, Webcast Dec. 18 At 8:30 a.m. EST To Discuss Berubicin For Treatment Of Glioblastoma Multiforme, Planned Phase 2 Trial   Benzinga
04:05PM EST  CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2   PR Newswire
09:30AM EST  CNS Pharmaceuticals Inc. (CNSP) said Thursday that the US Food and Drug Administration has approved the Investigational New Drug or IND application for the company's lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme or GBM.   RTTNews
09:11AM EST  CNS Pharma Says FDA Oks IND Application For Brain Cancer Drug Candidate Berubicin; Stock Surges   RTTNews
09:02AM EST  CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain   PR Newswire
09:01AM EST  CNS Pharmaceuticals Announces FDA Approval Of IND Application For Its Brain Cancer Drug Candidate Berubicin   Benzinga
Dec 16, 2020
08:30AM EST  InvestorBrandNetwork Announces Want Money Got   GlobeNewswire Inc
Nov 24, 2020
08:00AM EST  CNS Pharmaceuticals Featured in Syndicated Broadcast Covering   GlobeNewswire Inc
Nov 19, 2020
08:02AM EST  CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020   PR Newswire
Nov 18, 2020
08:01AM EST  CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium   PR Newswire
Nov 17, 2020
08:07AM EST  CNS Pharmaceuticals Submits IND Application To FDA For Berubicin   RTTNews
08:02AM EST  CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug   PR Newswire
08:01AM EST  CNS Pharmaceuticals Announces FDA Filing Of IND For Brain Cancer Drug Berubicin   Benzinga
Nov 12, 2020
08:21AM EST  CNS Pharmaceuticals To Discuss Phase 2 Clinical Trial Design To Be Submitted For FDA Review In Webcast At 4:30 p.m. EST Today   Benzinga
08:01AM EST  CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted   PR Newswire
Nov 9, 2020
08:09AM EST  CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review   Benzinga
08:01AM EST  CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2   PR Newswire
Oct 29, 2020
08:35AM EDT  CNS Pharmaceuticals Completes Manufacturing Of Berubicin For Phase 2 Clinical Trial   Benzinga
08:18AM EDT  CNS Pharma Says Completes Manufacturing Of Berubicin For Phase 2 Clinical Trial   RTTNews
08:02AM EDT  CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical   PR Newswire
Oct 20, 2020
08:13AM EDT  CNS Pharma Completes U.S. Manufacturing Of Berubicin For Phase 2 Clinical Trial   RTTNews
08:08AM EDT  CNS Pharmaceuticals Completes US Manufacturing Of Berubicin For Phase 2 Clinical Trial   Benzinga
08:02AM EDT  CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2   PR Newswire
Oct 12, 2020
08:00AM EDT  CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing   PR Newswire
Oct 9, 2020
08:05AM EDT  CNS Pharma Begins Manufacturing Of Berubicin In Europe   RTTNews
08:00AM EDT  CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe   PR Newswire
Oct 1, 2020
08:15AM EDT  CNS Pharmaceuticals GMP Manufacturer Partner NCK A/S Receives Certificate of Analysis For Active Pharma Ingredient   Benzinga
08:01AM EDT  CNS Pharmaceuticals Achieves Critical Manufacturing Milestone   PR Newswire
Sep 24, 2020
08:25AM EDT  CNS Pharmaceuticals Selects Image Analysis Group As Image Partner For Upcoming Berubicin Clinical Trials   RTTNews
08:13AM EDT  CNS Pharmaceuticals Selects Image Analysis Group As Image Partner For Berubicin Trials   Benzinga
08:01AM EDT  CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development   PR Newswire
08:00AM EDT  via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group (IAG) as the image partner for its upcoming Berubicin clinical trials.   GlobeNewswire Inc
Sep 17, 2020
11:41AM EDT  CNS Pharmaceuticals Sub-Licensee Partner Announces CRO For Phase 1, Phase 2 Berubicin Trials In Poland   Benzinga
08:01AM EDT  CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences   PR Newswire
Sep 11, 2020
08:00AM EDT  CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global   PR Newswire
Sep 3, 2020
08:18AM EDT  CNS Pharma Provides Update On Progress For U.S. Manufacturing Of Berubicin   RTTNews
08:08AM EDT  CNS Pharmaceuticals Announces Achieved Several Key US Drug Manufacturing Milestones   Benzinga
08:01AM EDT  CNS Pharmaceuticals Announces US Drug Manufacturing Milestones   PR Newswire
Aug 27, 2020
08:02AM EDT  Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board   PR Newswire
Aug 25, 2020
08:44AM EDT  CNS Provides Update On Plans For Berubicin; Anticipates Submitting IND To FDA This Year   RTTNews
08:42AM EDT  CNS Provides FDA Update On Berubicin IND Filing; Anticipates Submitting IND And Initiating Clinical Trials In Early 2021   Benzinga
08:40AM EDT  CNS Provides FDA Update on IND Filing   PR Newswire
Aug 24, 2020
09:34AM EDT  Benzinga's Top Upgrades, Downgrades For August 24, 2020   Benzinga
07:34AM EDT  Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11   Benzinga
Aug 20, 2020
08:15AM EDT  CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials   Benzinga
Aug 13, 2020
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 11, 2020
08:02AM EDT  CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday,   PR Newswire
Jul 22, 2020
08:01AM EDT  CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day   PR Newswire
Jul 15, 2020
08:15AM EDT  CNS Pharma Completes Drug Product Manufacturing Strategy For Berubicin API And Shipped API To Two Companies, Pii And BSP   RTTNews
08:02AM EDT  CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC